In This Article:
It's been a good week for Biodesix, Inc. (NASDAQ:BDSX) shareholders, because the company has just released its latest annual results, and the shares gained 4.6% to US$0.87. Revenue hit US$71m in line with forecasts, although the company reported a statutory loss per share of US$0.33 that was somewhat smaller than the analysts expected. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.
View our latest analysis for Biodesix
Taking into account the latest results, the consensus forecast from Biodesix's six analysts is for revenues of US$93.0m in 2025. This reflects a substantial 30% improvement in revenue compared to the last 12 months. Losses are predicted to fall substantially, shrinking 30% to US$0.21. Before this latest report, the consensus had been expecting revenues of US$93.6m and US$0.22 per share in losses. So there seems to have been a moderate uplift in analyst sentiment with the latest consensus release, given the upgrade to loss per share forecasts for this year.
Even with the lower forecast losses, the analysts lowered their valuations, with the average price target falling 27% to US$3.10. It looks likethe analysts have become less optimistic about the overall business. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. Currently, the most bullish analyst values Biodesix at US$3.50 per share, while the most bearish prices it at US$3.00. The narrow spread of estimates could suggest that the business' future is relatively easy to value, or thatthe analysts have a strong view on its prospects.
Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. It's clear from the latest estimates that Biodesix's rate of growth is expected to accelerate meaningfully, with the forecast 30% annualised revenue growth to the end of 2025 noticeably faster than its historical growth of 11% p.a. over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 7.1% annually. Factoring in the forecast acceleration in revenue, it's pretty clear that Biodesix is expected to grow much faster than its industry.